GFAP antibody

Catalog No. ABIN335357

The Mouse Monoclonal anti-GFAP antibody has been validated for WB, IHC, IHC (p) and IHC (fro). It is suitable to detect GFAP in samples from Human. There is 1 publication available.

Quick Overview for GFAP antibody (ABIN335357)

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This GFAP antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: 6F2

Product Details anti-GFAP Antibody

Specificity: Human.

Purification: Purified

Immunogen: 6F2 is a mouse monoclonal IgG1 antibody derived by fusion of mouse myeloma cells with spleen cells from a mouse immunized with glial fibrillary acidic protein from human brain.

Isotype: IgG1

Application Details

Application Notes: 6F2 reacts exclusively with glial fibrillary acidic protein which is present in astrocytes in the central nervous system and Schwann cells. 6F2 is suitable for immunoblotting and immunohistochemistry on frozen and paraffin-embedded tissues. Optimal antibody dilution should be determined by titration, recommended range is 1:25 - 1:200 for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1:100 - 1:1000 for immunoblotting applications.

Restrictions: For Research Use only

Handling

Storage: 4 °C

References for anti-GFAP antibody (ABIN335357)

Van Muijen, Ruiter, Warnaar: "Coexpression of intermediate filament polypeptides in human fetal and adult tissues." in: Laboratory investigation; a journal of technical methods and pathology, Vol. 57, Issue 4, pp. 359-69, (1987) (PubMed).

Target Details for GFAP

Target: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Alternative Name: Glial fibrillary acidic protein / GFAP

Background: GFAP (55 kD) is selectively located in astrocytes and represents the major constituent of astrocytic intermediate filaments. GFAP expression levels are highly variable during development of the central nervous system. In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer€™s disease, epilepsy and multiple sclerosis. In the peripheral nervous system GFAP is expressed by Schwann cells. Upon differentiation, myelin forming Schwann cells down-regulate GFAP, whereas in non-myelin forming Schwann cells GFAP persists into adulthood.